No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease--a randomized placebo-controlled study.
The balance between different immunological stimuli is essential in the progression and stabilization of atherosclerotic plaques . Immune regulation has been suggested as potential target for the treatment of atherosclerotic disease . We sought to determine whether treatment with pentoxifylline , a phosphodiesterase inhibitor with immunomodulating properties , could reduce the pro-inflammatory response observed in patients with acute coronary syndromes ( ACS ) and increase anti-inflammatory activity . In a double-blind , prospect i ve , placebo-controlled study , 64 patients with ACS were r and omized to receive pentoxifylline 400 mg TID or placebo for 6 months . Analysis of the pro-inflammatory markers , C-reactive protein ( CRP ) , interleukin (IL)-6 , IL-12 , interferon-gamma and tumor necrosis factor (TNF)-alpha and the anti-inflammatory cytokines , transforming growth factor (TGF)-beta1 and IL-10 were done at baseline , 1 and 6 months . Pentoxifylline treatment significantly reduced the adjusted levels of CRP and TNF-alpha compared to placebo after 6 months ( P=0.04 and P<0.01 , respectively ) . IL-12 increase was significantly less pronounced with pentoxifylline ( P=0.04 ) . The levels of the anti-inflammatory cytokine , IL-10 , also declined significantly less in the pentoxifylline group compared to placebo ( P<0.01 ) with a trend towards a higher increase of TGF-beta1 in the former group ( P=0.16 ) . Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory response in patients with ACS and may have beneficial clinical effects on cardiovascular events
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .